Primary prophylaxis of sudden death in hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, and dilated cardiomyopathy

George J Klein; Andrew D Krahn; Allan C Skanes; Raymond Yee; Lorne J Gula

doi:10.1111/j.1540-8167.2005.50116.x

Primary prophylaxis of sudden death in hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, and dilated cardiomyopathy

J Cardiovasc Electrophysiol. 2005 Sep:16 Suppl 1:S28-34. doi: 10.1111/j.1540-8167.2005.50116.x.

Authors

George J Klein¹, Andrew D Krahn, Allan C Skanes, Raymond Yee, Lorne J Gula

Affiliation

¹ Division of Cardiology, University of Western Ontario, London, Ontario, Canada. [email protected]

PMID: 16138882
DOI: 10.1111/j.1540-8167.2005.50116.x

Abstract

We present an evidence-based overview of primary prevention of sudden cardiac death. Several recent studies have provided important data regarding pharmacologic and device-based therapy for patients with conditions that confer high risk for sudden death. A rational approach to these therapies, with emphasis on implanted cardiovertor defibrillators, is discussed.

Publication types

Review

MeSH terms

Anti-Arrhythmia Agents / therapeutic use*
Cardiomyopathies / diagnosis
Cardiomyopathies / mortality*
Cardiomyopathies / therapy*
Clinical Trials as Topic
Comorbidity
Death, Sudden, Cardiac / epidemiology*
Death, Sudden, Cardiac / prevention & control*
Electric Countershock / statistics & numerical data*
Evidence-Based Medicine
Humans
Practice Guidelines as Topic
Practice Patterns, Physicians'
Prevalence
Primary Health Care / statistics & numerical data
Risk Assessment / methods*
Risk Factors
Treatment Outcome

Substances

Anti-Arrhythmia Agents